Sotaniemi K - Search Results

1

[Update on current care guidelines. Parkinson's disease].

Reijo M, Atula S, Heikkinen E, Jaakkola MR, Pekka J, Keränen T, Martikainen K, Pekkonen E, Sotaniemi K; Suomalaisen Lääkäriseuran Duodecimin ja Suomen Neurologisen Yhdistyksen Asettama Työryhmä. Reijo M, et al. Among authors: sotaniemi k. Duodecim. 2010;126(19):2289-90. Duodecim. 2010. PMID: 21086687 Finnish.

2

Parkinsonin tauti.

Marttila R, Heikkinen E, Hänninen J, Jousilahti P, Jäättelä A, Kaakkola S, Keränen T, Sotaniemi K, Teräväinen H. Marttila R, et al. Among authors: sotaniemi k. Duodecim. 2006;122(21):2655-6. Duodecim. 2006. PMID: 17233345 Finnish. No abstract available.

3

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.

Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keränen T. Myllylä VV, et al. Among authors: sotaniemi ka. Eur J Clin Pharmacol. 1993;45(5):419-23. doi: 10.1007/BF00315512. Eur J Clin Pharmacol. 1993. PMID: 8112370 Clinical Trial.

4

Stereotactic radiotherapy instead of conventional epilepsy surgery. A case report.

Heikkinen ER, Heikkinen MI, Sotaniemi K. Heikkinen ER, et al. Among authors: sotaniemi k. Acta Neurochir (Wien). 1992;119(1-4):159-60. doi: 10.1007/BF01541801. Acta Neurochir (Wien). 1992. PMID: 1481742

5

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.

Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK. Olanow CW, et al. Among authors: sotaniemi ka. Neurology. 1998 Sep;51(3):825-30. doi: 10.1212/wnl.51.3.825. Neurology. 1998. PMID: 9748034

6

[Heart disease and cerebrovascular disorders].

Sotaniemi K, Ikäheimo M. Sotaniemi K, et al. Duodecim. 1989;105(7):642-50. Duodecim. 1989. PMID: 2656213 Review. Finnish. No abstract available.

7

Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.

Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Ikola O, Heinonen EH. Myllylä VV, et al. Among authors: sotaniemi ka. Acta Neurol Scand. 1997 Apr;95(4):211-8. doi: 10.1111/j.1600-0404.1997.tb00101.x. Acta Neurol Scand. 1997. PMID: 9150811 Clinical Trial.

8

Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.

Turkka J, Suominen K, Tolonen U, Sotaniemi K, Myllylä VV. Turkka J, et al. Among authors: sotaniemi k. Neurology. 1997 Mar;48(3):662-7. doi: 10.1212/wnl.48.3.662. Neurology. 1997. PMID: 9065544 Clinical Trial.

9

Suppressed sympathetic skin response in Parkinson disease.

Haapaniemi TH, Korpelainen JT, Tolonen U, Suominen K, Sotaniemi KA, Myllylä VV. Haapaniemi TH, et al. Among authors: sotaniemi ka. Clin Auton Res. 2000 Dec;10(6):337-42. doi: 10.1007/BF02322257. Clin Auton Res. 2000. PMID: 11324989 Clinical Trial.

10

Economic burden and quality of life impairment increase with severity of PD.

Keränen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, Kola H, Ylikoski A, Satomaa O, Kovanen J, Taimela E, Haapaniemi H, Turunen H, Takala A. Keränen T, et al. Among authors: sotaniemi k. Parkinsonism Relat Disord. 2003 Jan;9(3):163-8. doi: 10.1016/s1353-8020(02)00097-4. Parkinsonism Relat Disord. 2003. PMID: 12573872

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page